Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cladribine + cytarabine + granulocyte colony stimulating factor
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination chemotherapy regimen consisting of cladribine (a purine nucleoside analog), cytarabine (an antimetabolite), and granulocyte colony stimulating factor (G-CSF, a hematopoietic growth factor). The combination is primarily used in the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). Cladribine inhibits DNA synthesis by incorporating into DNA and causing strand breaks. Cytarabine also inhibits DNA synthesis by acting as an antimetabolite. G-CSF stimulates the production of neutrophils and may sensitize leukemic cells to chemotherapy while supporting recovery from myelosuppression. This regimen has demonstrated significant efficacy in R/R AML with high remission rates and manageable toxicity profiles[1][5][6].
- Other names
- cladribine + cytarabine + G-CSFCLAGCLAG regimen
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)DNA polymerase family
Beyond the preview
Go deeper on cladribine + cytarabine + granulocyte colony stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cladribine + cytarabine + granulocyte colony stimulating factor.